Skip to main content
    O

    Ocular Therapeutix Inc (OCUL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.01
    -0.20 (-3.22%)

    Market Cap: $1.37B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ocular Therapeutix Inc (OCUL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Ocular Therapeutix reported revenue of $51.95M for the fiscal year ended Dec 31, 2025, down 18.5% from the year before. That year, net income was -$265.94M with a net margin of -511.9%, operating cash flow was -$204.88M and free cash flow was -$216.89M. The quarter ended Sep 30, 2026 had revenue of $12.87M and net income of -$94.78M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $1.89M, a compound annual rate of 44.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$51.95M-18.5%87.3%-519.8%-511.9%
    Dec 2024$63.72M+9.0%91.2%-269.6%-303.7%
    Dec 2023$58.44M+13.5%91.0%-141.0%-138.1%
    Dec 2022$51.49M+18.3%91.2%-152.7%-138.0%
    Dec 2021$43.52M+150.1%89.9%-179.3%-15.1%
    Dec 2020$17.40M+311.7%88.0%-361.1%-894.3%
    Dec 2019$4.23M+112.4%45.0%-2029.9%-2043.3%
    Dec 2018$1.99M+3.5%76.6%-2970.8%-3014.0%
    Dec 2017$1.92M+1.9%76.2%-3220.1%-3296.2%
    Dec 2016$1.89MN/A76.5%-2296.0%-2369.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$51.95M$63.72M$58.44M$51.49M$43.52M$17.40M$4.23M$1.99M$1.92M$1.89M
    Cost of revenue$6.57M$5.63M$5.28M$4.54M$4.41M$2.08M$2.33M$465.00K$457.00K$443.00K
    Gross profit$45.38M$58.10M$53.16M$46.95M$39.12M$15.32M$1.90M$1.52M$1.47M$1.44M
    Research and development$197.10M$127.64M$61.05M$53.46M$50.08M$28.69M$41.09M$36.91M$30.88M$27.07M
    Operating income-$270.02M-$171.78M-$82.38M-$78.65M-$78.04M-$62.85M-$85.80M-$59.12M-$61.92M-$43.33M
    Net income-$265.94M-$193.51M-$80.74M-$71.04M-$6.55M-$155.64M-$86.37M-$59.98M-$63.39M-$44.70M
    EBITDA-$264.77M-$164.74M-$78.48M-$57.85M$7.13MN/A-$75.29M-$56.44M-$59.87M-$41.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$12.87M$13.47M$10.79M$13.25M$14.54M$13.46M$10.70M$17.08M$15.43M$16.44M$14.77M$14.80M
    Gross profit$11.42M$11.46M$9.46M$11.66M$12.77M$11.52M$9.44M$15.85M$13.86M$14.93M$13.45M$13.42M
    Operating income-$97.86M-$82.11M-$93.34M-$69.76M-$68.70M-$67.64M-$63.92M-$50.58M-$46.00M-$43.59M-$31.62M-$20.05M
    Net income-$94.78M-$78.76M-$88.61M-$64.65M-$69.42M-$67.81M-$64.05M-$48.39M-$36.49M-$43.78M-$64.85M-$29.22M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $74.15M by $662.91M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$808.06M$457.94M$252.06M$149.29M$204.89M$261.86M$78.74M$73.04M$55.43M$74.94M
    Current assets$782.13M$440.99M$232.24M$129.63M$191.30M$246.16M$60.17M$56.19M$43.34M$69.90M
    Cash and equivalents$737.06M$392.10M$195.81M$102.30M$164.16M$228.06M$54.44M$54.06M$41.54M$32.94M
    Total liabilities$153.75M$142.59M$160.93M$113.91M$116.89M$185.77M$82.37M$37.17M$29.28M$22.93M
    Short-term debt$2.82M$1.93M$1.59M$1.60M$1.62M$8.29M$0N/A$5.54M$1.55M
    Long-term debt$71.34M$68.50M$74.92M$54.01M$51.44M$41.24M$49.31M$24.79M$12.47M$14.09M
    Shareholder equity$654.31M$315.34M$91.13M$35.38M$88.00M$76.09M-$3.63M$35.88M$26.15M$52.01M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$605.65M$671.32M$732.53M$808.06M$410.88M$451.33M$405.92M$457.94M$490.37M$517.09M$538.95M$252.06M
    Total liabilities$164.70M$151.28M$150.96M$153.75M$152.65M$145.42M$139.99M$142.59M$138.35M$139.40M$130.96M$160.93M
    Cash and equivalents$530.61M$598.64M$666.70M$737.06M$344.77M$391.13M$349.68M$392.10M$427.22M$459.69M$482.89M$195.81M
    Shareholder equity$440.95M$520.04M$581.57M$654.31M$258.23M$305.92M$265.93M$315.34M$352.02M$377.69M$407.98M$91.13M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$204.88M-$134.68M-$70.23M-$59.60M-$65.55M-$53.55M-$77.58M-$49.23M-$50.47M-$34.00M
    Capital expenditures$12.01M$1.29M$6.09M$3.71M$1.19M$841.00K$2.24M$1.89M$8.25M$1.92M
    Free cash flow-$216.89M-$135.97M-$76.32M-$63.32M-$66.74M-$54.40M-$79.82M-$51.12M-$58.73M-$35.92M
    Dividends paidN/AN/A$52.57MN/A$710.00K$747.00K$37.27M$297.00K$4.38M$0
    Share repurchasesN/AN/AN/AN/A$275.00K$0$0N/AN/AN/A
    Investing cash flow-$11.88M-$1.29M-$6.09M-$3.71M-$1.19M-$841.00K-$2.24M-$1.89M$26.95M$37.07M
    Financing cash flow$561.72M$332.11M$169.83M$1.45M$2.85M$228.01M$75.34M$68.64M$32.01M$585.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$65.62M-$67.27M-$65.99M-$54.25M-$50.73M-$55.24M-$44.67M-$39.43M-$36.56M-$24.80M-$33.89M-$22.45M
    Capital expenditures$3.03M$3.37M$4.66M$2.84M$5.99M$1.25M$1.93M$202.00K$89.00K$742.00K$255.00K$459.00K
    Free cash flow-$68.65M-$70.64M-$70.66M-$57.09M-$56.72M-$56.48M-$46.60M-$39.63M-$36.65M-$25.54M-$34.14M-$22.91M
    Last 12 quarters

    Frequently Asked Questions About OCUL

    What is Ocular Therapeutix's annual revenue?

    Ocular Therapeutix reported revenue of $51.95M for the fiscal year ended Dec 31, 2025.

    How fast is Ocular Therapeutix's revenue growing?

    Revenue was down 18.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.3%.

    Is Ocular Therapeutix profitable?

    No. Ocular Therapeutix reported net income of -$265.94M for the fiscal year ended Dec 31, 2025, with a net margin of -511.9%.

    How much free cash flow does OCUL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$204.88M minus capital expenditures of $12.01M produced free cash flow of -$216.89M.

    How much debt does Ocular Therapeutix have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $71.34M, short-term debt of $2.82M and cash and equivalents of $737.06M.